Kissei Applies For Approval In Japan For Second-Generation Urief
This article was originally published in PharmAsia News
Matsumoto, Japan-based Kissei Pharmaceutical Co. is applying for approval for its second-generation dysuria drug Urief. Compared to the current Urief capsules, the new tablet form will be smaller in size and easier to swallow. Urief treats urination difficulties by enabling the prostate muscles to relax to improve urethra resistance. Jointly developed by Kissei and Daiichi Pharmaceutical Co. (now Daiichi Sankyo), Urief was originally launched in May 2006. Kissei hopes that as the Japanese population ages and more patients suffer urination difficulties, the new easy-to-swallow tablet will result in an increase in sales. The new product is expected to launch in 2009. (Click here for more - may require subscription.)
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.